Oxford Immunotec Global PLC Ordinary Shares
OXFD
OXFD was delisted on the 5th of March, 2021.
80 hedge funds and large institutions have $310M invested in Oxford Immunotec Global PLC Ordinary Shares in 2017 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 32 increasing their positions, 22 reducing their positions, and 3 closing their positions.
400% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 3
181% more capital inflows, than outflows
Capital inflows: $60.5M | Capital outflows: $21.5M
45% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 22
10% more funds holding
Funds holding: 73 → 80 (+7)
7.2% more ownership
Funds ownership: 81.03% → 88.23% (+7.2%)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$14.3M |
| 2 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$7.93M |
| 3 |
Polar Capital
London,
United Kingdom
|
+$4.61M |
| 4 |
Axa
Paris,
France
|
+$4.51M |
| 5 |
Redmile Group
San Francisco,
California
|
+$4.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Clarus Ventures
Cambridge,
Massachusetts
|
-$10.2M |
| 2 |
New Leaf Venture Partners
New York
|
-$3.21M |
| 3 |
First Light Asset Management
Edina,
Minnesota
|
-$1.79M |
| 4 |
Acuta Capital Partners
Redwood City,
California
|
-$1.21M |
| 5 |
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$1.02M |
OXFD Hedge Fund Activity: Q1 2017 in Review
80 of the 4,035 institutional investors tracked by Wall St. Rank reported a position in Oxford Immunotec Global PLC Ordinary Shares (OXFD) for Q1 2017, worth a combined $310M — up 13% from $274M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new OXFD positions and 3 closed out — a net gain of 12 holders — while 32 added to existing stakes and 22 trimmed.
The largest buyer was BlackRock, adding an estimated $14.3M. The largest seller was Clarus Ventures, cutting an estimated $10.2M.
- 80 institutional investors held Oxford Immunotec Global PLC Ordinary Shares (OXFD) as of Q1 2017, up from 73 in Q4 2016.
- Funds reported $310M of Oxford Immunotec Global PLC Ordinary Shares stock for Q1 2017, up 13% quarter-over-quarter.
- 15 funds opened new Oxford Immunotec Global PLC Ordinary Shares positions in Q1 2017 and 3 closed out, a net change of +12 holders.
- The largest Oxford Immunotec Global PLC Ordinary Shares buyer in Q1 2017 was BlackRock, an estimated $14.3M added.
- The largest Oxford Immunotec Global PLC Ordinary Shares seller in Q1 2017 was Clarus Ventures, an estimated $10.2M sold.
Based on aggregated 13F filings for Q1 2017.